Public Employees Retirement System of Ohio Takes $13.99 Million Position in United Therapeutics Corporation $UTHR

Public Employees Retirement System of Ohio purchased a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 25,816 shares of the biotechnology company’s stock, valued at approximately $13,988,000.

Other large investors have also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in United Therapeutics during the second quarter valued at $2,868,735,000. Wellington Management Group LLP lifted its position in shares of United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after buying an additional 1,042,711 shares during the last quarter. Jupiter Topco LLC acquired a new position in shares of United Therapeutics in the 2nd quarter valued at about $450,140,000. Norges Bank bought a new stake in shares of United Therapeutics during the 4th quarter valued at about $293,418,000. Finally, Avoro Capital Advisors LLC grew its position in shares of United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after buying an additional 383,838 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Royal Bank Of Canada lowered their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Morgan Stanley set a $515.00 price target on United Therapeutics in a research report on Thursday, August 6th. JPMorgan Chase & Co. raised their price target on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Finally, Weiss Ratings lowered United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $646.00.

United Therapeutics Price Performance

United Therapeutics stock opened at $515.46 on Monday. United Therapeutics Corporation has a 52-week low of $303.08 and a 52-week high of $609.35. The firm has a market capitalization of $22.11 billion, a price-to-earnings ratio of 18.44, a PEG ratio of 1.75 and a beta of 0.59. The firm has a 50-day moving average price of $530.46 and a two-hundred day moving average price of $539.16.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating the consensus estimate of $6.86 by $0.41. The company had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. United Therapeutics’s revenue was down 1.9% compared to the same quarter last year. During the same quarter last year, the business earned $6.41 earnings per share. Research analysts expect that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

Insider Buying and Selling

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $547.61, for a total transaction of $5,202,295.00. Following the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at $22,185,323.93. The trade was a 19.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $546.28, for a total value of $5,462,800.00. Following the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,311,581.28. This trade represents a 34.63% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 404,575 shares of company stock valued at $216,652,640 over the last three months. Corporate insiders own 8.60% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.